Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease (NDD) characterized by dementia among old age subjects. In spite of the intense and persistent effects of AD, currently available therapeutic modalities demonstrated unsatisfactory results and couldn't stop disease progression. Dasatinib is a tyrosine kinase (TK) inhibitor (TKI) that has immunomodulatory characteristics and could cross the blood-brain barrier (BBB). It's an FDA-approved drug utilized to treat resistant lymphoblastic or chronic myeloid leukemia (CML) in those who didn't respond to preceding therapies. Objectives: This literature was conducted to assess the role of dasatinib an AD. Methods: Data were collected from online review articles and papers from the PubMed, Science direct and Google scholar. We searched for Alzheimer's disease, Dasatinib, Dementia and Tyrosine kinase. The authors also reviewed references from pertinent literature, however only the most recent or comprehensive studies from 2006 to 2024 were included. Documents in languages other than English were disqualified due to lack of translation-related sources. Papers such as unpublished manuscripts, oral presentations, conference abstracts, and dissertations that were not part of larger scientific studies were excluded. Conclusion: Dasatinib appears to be a talentedtherapy of AD. Dasatinib not only attenuate amyloid and tau proteins, which are the main feature of AD pathology, but also has very important immune-modulatory function as it decreases pro-inflammatory markers and increasing anti-inflammatory cytokines (i.e. IL-10). Furthermore, dasatinib decreases activated microglia, and acts as a senolytic drug decreasing senescent cells (SnCs) in brain.